Defendant: Nutramax Laboratories, Inc. and Nutramax Laboratories Veterinary Sciences, Inc. | Category: Consumer Products & Retail | Added: 2026-07-08
Alleged Issue
Nutramax allegedly marketed Cosequin canine joint supplements as having therapeutic value for joint health that was not adequately supported by clinical evidence.
Eligibility
California residents who purchased qualifying Cosequin canine joint supplement products for personal use between May 3, 2016 and May 6, 2022.
Estimated Payout
$25 per unit purchased on attestation alone (no proof of purchase required), up to a household maximum of $150; drawn from an $11.5 million settlement fund.